EV71 vaccine

Vaccine is the most effective way to prevent enterovirus infection. MVC develops the first EV71 vaccine extending protection to high risk population ages 2-6 months old.

more
Pandemic influenza vaccines

MVC establishes core-dossier and mammalian cell manufacturing platform for H5N1 and H7N9 mock-up vaccines, thus capable to speed up vaccine accessibility during pandemic.

more
Dengue vaccine

MVC’s dengue vaccine is able to elicit thorough protection to all four serotypes of dengue viruses with just one single dose.

more
Anti-RSV Biosimilar

MVC partners with WHO to develop biosimilar Palivizumab, providing affordable and high quality preventative medications for global community.

more